Cushing's Disease & Skin Problems in Dogs: Dermatological Signs & Management

Based on peer reviewed veterinary research · For educational purposes only · Updated October 2026 · 11 min read

Photo by Tima Miroshnichenko on Pexels

Introduction

Cushing's disease represents one of the most common endocrine disorders in dogs, particularly affecting senior and middle-aged canines. While veterinarians and owners typically associate this condition with metabolic dysfunction, excessive thirst, urination, and appetite, the dermatological manifestations are equally significant and often serve as the earliest clinical indicators. The skin changes accompanying canine hyperadrenocorticism are not merely cosmetic concerns; they reflect profound physiological dysfunction that directly impacts a dog's comfort, susceptibility to secondary infections, and overall quality of life.

The relationship between excessive cortisol and cutaneous health is complex and multifaceted. Cortisol, while essential for normal immune function and stress response at physiological levels, becomes profoundly immunosuppressive and tissue-destructive when chronically elevated. The skin bears witness to this endocrine dysregulation through characteristic patterns of hair loss, abnormal keratinization, inflammatory changes, and compromised barrier function. Understanding these dermatological manifestations is essential for early recognition, appropriate diagnosis, and optimal management strategies that address both the underlying hormonal disorder and its cutaneous consequences.

What Is Cushing's Disease?

Understanding Hyperadrenocorticism in Canines

Cushing's disease, medically termed spontaneous hyperadrenocorticism, is an endocrine disorder characterized by excessive cortisol production. In approximately 80 to 85% of cases, the condition originates from a functional pituitary tumor (pituitary-dependent hyperadrenocorticism, or PDH), which abnormally stimulates the adrenal glands via excessive ACTH (adrenocorticotropic hormone) secretion. The remaining 15 to 20% of cases involve primary adrenal tumors or carcinomas that independently produce excessive cortisol without pituitary dysregulation.

The syndrome typically emerges in dogs aged 8 to 12 years, though it can occur in younger animals. Certain breeds demonstrate increased predisposition, including Poodles, Dachshunds, Beagles, and Boxers, suggesting genetic factors may influence disease susceptibility. The pathophysiology involves loss of normal hypothalamic-pituitary-adrenal (HPA) axis feedback inhibition, resulting in unregulated cortisol production that exceeds physiological requirements by several-fold.

Cortisol's Effects on Skin Physiology

Cortisol profoundly influences multiple aspects of cutaneous function, from cellular turnover to immune surveillance to barrier integrity. At excessive concentrations, cortisol:

• Inhibits fibroblast function, reducing collagen synthesis and resulting in skin atrophy and reduced tensile strength
• Suppresses local and systemic immunity, impairing the skin's capacity to resist bacterial and fungal colonization
• Disrupts lipid metabolism in the stratum corneum, compromising the barrier function critical for preventing transepidermal water loss
• Alters hair follicle cycling, pushing follicles from anagen (growth) to telogen (resting) phases, causing symmetrical alopecia
• Promotes abnormal keratinization, leading to comedone formation, seborrhea, and altered skin texture
• Reduces wound healing capacity through multiple mechanisms, including impaired angiogenesis and collagen remodeling
• Triggers ectopic mineralization in dermis and subcutaneous tissues, manifesting as calcinosis cutis

Dermatological Signs of Cushing's Disease

The cutaneous manifestations of canine hyperadrenocorticism are remarkably consistent and often diagnostically suggestive. These changes reflect the systemic nature of cortisol excess and typically precede or coincide with systemic signs. Recognition of these dermatological patterns facilitates earlier diagnosis and intervention.

Bilaterally Symmetrical Alopecia

Hair loss in Cushing's disease presents with a characteristic bilaterally symmetrical pattern, reflecting the systemic nature of the underlying hormonal disorder. The alopecia typically initiates over the trunk, dorsum, and proximal extremities, sparing the head and distal limbs initially. This distinctive distribution pattern helps differentiate Cushing's-associated alopecia from allergic alopecia, which is often more focal or random in distribution.

The pathophysiology involves cortisol-mediated alteration of hair follicle cycling, pushing follicles into prolonged telogen (resting) phases while suppressing anagen (growth) phases. This results in telogen effluvium with subsequent hair shedding without regrowth. Histopathologically, affected follicles demonstrate keratinization abnormalities and reduced melanin production. The alopecia is non-pruritic unless secondary bacterial or fungal infection develops. In advanced cases, alopecia may progress to near-complete denudation of the trunk and proximal extremities, significantly compromising the skin's protective function.

Skin Atrophy and Fragility

Chronic cortisol excess produces remarkable skin atrophy, transforming normally elastic, resilient skin into paper-thin, fragile tissue. This phenomenon results from cortisol-mediated inhibition of dermal fibroblasts and reduced collagen synthesis, particularly Type I collagen, which comprises approximately 80% of skin's structural matrix. The resulting epidermis and dermis become measurably thinner, with visible reduction in skin elasticity and turgor.

Clinically, affected skin appears translucent and may display prominent vascular patterns normally obscured by more robust dermis. Owners often report the skin feels like "crepe paper" or "tissue paper" when touched. This atrophy has serious functional consequences: the compromised skin barrier permits easier bacterial and fungal invasion, impairs wound healing, and increases susceptibility to mechanical trauma, even from routine play or minor contact. Affected dogs are prone to spontaneous skin tears or lacerations that would be minor in healthy skin but may require intervention in severely atrophic integument.

Calcinosis Cutis

Calcinosis cutis, abnormal calcium deposition in the dermis and subcutaneous tissues, is a relatively pathognomonic sign of canine hyperadrenocorticism, occurring in approximately 10 to 25% of affected dogs. The condition results from cortisol-mediated alterations in mineral metabolism, including increased renal calcium reabsorption, enhanced intestinal calcium absorption, and direct effects on dermal mineralization mechanisms.

Calcinosis typically manifests over weight-bearing areas, dorsal midline, and areas of chronic friction. Affected skin displays firm, nodular deposits that may feel gritty upon palpation. These deposits can ulcerate, becoming sites of secondary infection and significant discomfort. Diagnosis is confirmed through radiography or fine-needle aspiration demonstrating calcium deposition. Unlike other Cushing's-related skin changes, calcinosis cutis may persist even after successful normalization of cortisol levels, sometimes requiring months to years for resolution.

Comedones and Seborrheic Changes

Excessive cortisol profoundly disrupts normal keratinization processes, resulting in abnormal accumulation of keratin within hair follicles and on the skin surface. This manifests as widespread comedone formation, appearing as small black or dark-colored plugs, most prominently on the ventral abdomen and inner thighs. These comedones reflect both abnormal sebaceous gland function and impaired follicular epithelial maturation.

Associated seborrheic changes include scaly, flaky appearance, oily dermatitis, and malodorous skin. The skin becomes prone to seborrhea sicca (dry, scaly) or seborrhea oleosa (oily), with some dogs demonstrating alternating presentations. These changes are accompanied by altered sebaceous gland secretion and impaired lipid composition in the skin barrier, contributing to increased susceptibility to secondary bacterial and fungal colonization.

Poor Wound Healing

Dogs with Cushing's disease demonstrate markedly impaired wound healing capacity, reflecting cortisol's multiple suppressive effects on tissue repair mechanisms. Cortisol inhibits several critical phases of wound healing: it reduces angiogenesis (new blood vessel formation), impairs collagen deposition and remodeling, suppresses fibroblast proliferation, and reduces production of growth factors essential for tissue regeneration.

Clinical consequences include wounds remaining open or scabbed for extended periods, often with minimal evidence of healing progression. Even minor procedures such as biopsy or laceration repair may result in prolonged healing timelines. Owners report that minor wounds or scratches that normally heal within days may persist for weeks. This compromised healing capacity significantly impacts surgical outcomes and requires extended post-operative care intervals in affected animals.

Secondary Bacterial and Fungal Infections

Perhaps the most clinically significant dermatological consequence of Cushing's disease is the high incidence of secondary bacterial and fungal infections. Cortisol's profound immunosuppressive effects, reducing lymphocyte counts, impairing neutrophil function, suppressing local skin immunity, and compromising barrier integrity, create an ideal environment for opportunistic pathogens. Secondary pyoderma (bacterial skin infection) occurs in 50 to 80% of dogs with hyperadrenocorticism, while secondary Malassezia (yeast) dermatitis affects 25 to 50% of affected animals. Many dogs experience concurrent bacterial and fungal infection.

Secondary infections significantly amplify dermatological signs, adding pruritus, pustule formation, papules, and crusting to the underlying Cushing's-related alopecia. These infections are notoriously recurrent, as the underlying immunosuppressive state persists until cortisol levels normalize. Management often requires concurrent antimicrobial and antifungal therapy alongside primary endocrine treatment. Topical antimicrobial agents such as chlorhexidine spray may provide adjunctive benefit for superficial bacterial colonization.

Diagnosis of Cushing's Disease

Recognizing Diagnostic Patterns

While dermatological signs strongly suggest hyperadrenocorticism, definitive diagnosis requires endocrine testing that confirms excessive cortisol production. The clinical presentation, combining bilaterally symmetrical alopecia, skin atrophy, comedones, and secondary infections in a middle-aged to senior dog, should prompt immediate endocrine evaluation. Veterinarians should not dismiss cutaneous changes as merely allergic or idiopathic when this characteristic constellation of signs is present.

The diagnostic approach typically begins with baseline adrenal function tests. The two primary screening tests are the low-dose dexamethasone suppression (LDDS) test and the ACTH stimulation test. The LDDS test measures serum cortisol 4 to 6 hours after low-dose dexamethasone administration; failure of cortisol suppression indicates hyperadrenocorticism. The ACTH stimulation test measures baseline and post-ACTH cortisol levels; elevated post-stimulation cortisol indicates adrenal overactivity. Both tests have comparable sensitivity and specificity (approximately 85 to 90%), though the LDDS test is marginally more sensitive for detecting pituitary-dependent disease.

Once hyperadrenocorticism is confirmed, additional testing distinguishes pituitary-dependent from adrenal-dependent disease. High-dose dexamethasone suppression testing and plasma ACTH measurement typically differentiate between these etiologies, guiding treatment selection. Advanced imaging (MRI for pituitary assessment or CT/ultrasound for adrenal evaluation) may be pursued depending on treatment considerations.

Treatment & Skin Recovery

Endocrine Management and Hormonal Normalization

Treatment of hyperadrenocorticism fundamentally addresses the underlying endocrine disorder, which is essential for skin recovery. For pituitary-dependent disease (PDH), mitotane (lysodren) is the gold-standard treatment, while trilostane represents an alternative with potentially faster onset of action. Both medications inhibit cortisol synthesis at the adrenal level. Mitotane requires careful monitoring through serial ACTH stimulation testing to achieve therapeutic cortisol suppression while avoiding over-treatment. Trilostane, a 11β-hydroxylase inhibitor, offers reversible suppression of cortisol production, allowing more flexible dosing adjustments.

For adrenal-dependent disease, particularly adrenocortical tumors, surgical adrenalectomy offers the most definitive treatment, potentially achieving complete resolution of hyperadrenocorticism. However, surgery carries significant perioperative risks in older animals and requires experienced surgical expertise. Medical management with mitotane or trilostane provides an alternative when surgery is not feasible.

The timeline for hormonal normalization varies, typically requiring 2 to 4 weeks to achieve therapeutic cortisol suppression following initiation of medical therapy. However, skin recovery follows a delayed timeline, as the dermatological changes represent cumulative damage that requires time to repair. Even after normalization of cortisol levels, skin improvement may require 6 to 12 weeks or longer, depending on disease severity and individual healing capacity.

Management of Secondary Infections

Secondary bacterial and fungal infections require concurrent treatment alongside primary endocrine therapy. Appropriate antibiotic selection should ideally be guided by culture and sensitivity testing from affected skin, as many secondary pyodermas involve multidrug-resistant organisms, particularly in dogs with prolonged or recurrent infections. Fluoroquinolones or amoxicillin-clavulanate are common initial selections, though sensitivities must be verified.

Treatment duration for secondary pyoderma in Cushing's disease typically exceeds standard recommendations (3 to 4 weeks minimum) given the persistent immunosuppressive state. Some veterinarians recommend continuing antimicrobial therapy until cortisol levels normalize, then reassessing for infection resolution. Topical antimicrobial therapies, including chlorhexidine or benzoyl peroxide washes, provide adjunctive benefit for superficial or localized infections.

Secondary Malassezia dermatitis responds to azole antifungals (ketoconazole, itraconazole) or terbinafine. Topical antifungal agents including miconazole or chlorhexidine-containing products may provide additional benefit. Like antibacterial infections, fungal infections frequently recur until cortisol normalization, necessitating sustained antifungal coverage and close monitoring for relapse.

Supportive Dermatological Care

While endocrine and antimicrobial therapies address the primary and secondary disease drivers, supportive dermatological care optimizes skin healing and comfort. Regular bathing with mild, moisturizing cleansers removes scale and necrotic debris, reducing bacterial and fungal burden. Medicated shampoos containing chlorhexidine, miconazole, or tar may provide additional benefit for secondary infections or seborrheic changes.

Nutritional optimization supports healing. Elevated-quality protein intake is particularly important given the catabolic effects of excess cortisol and the demands of dermal regeneration. Essential fatty acid supplementation, particularly omega-3 polyunsaturated fatty acids (PUFA), may improve barrier function and reduce inflammation. Zinc, vitamin E, and vitamin A all play critical roles in keratinocyte function and wound healing; deficiencies should be corrected through appropriate supplementation.

Environmental modifications reduce mechanical trauma to fragile skin. Soft bedding, avoidance of rough play, and prevention of scratching through behavioral management all contribute to skin preservation during the recovery period. Affected dogs should be protected from extreme temperatures, as atrophic skin demonstrates reduced thermoregulatory capacity.

Prognosis and Long-Term Skin Outcomes

With appropriate medical management, most dogs with pituitary-dependent hyperadrenocorticism achieve hormonal control and experience significant improvement in dermatological signs over 2 to 6 months. Hair regrowth typically begins 4 to 8 weeks after cortisol normalization, progressing gradually toward baseline coat density. Skin atrophy gradually improves as fibroblasts resume normal collagen synthesis, though the skin may never completely return to pre-disease thickness, particularly in severely affected dogs.

Secondary infections, particularly recurrent pyoderma and Malassezia dermatitis, may persist briefly after hormonal normalization due to the extended timeline of immune reconstitution. Close monitoring and continued antimicrobial therapy may be warranted. Calcinosis cutis, while visible for months, typically resolves gradually as the body resorbs and clears the ectopic mineral deposits.

Long-term prognosis for skin recovery depends on treatment compliance, disease severity, and individual healing capacity. Dogs with mild disease and prompt diagnosis typically achieve excellent skin recovery. Those with advanced disease, prolonged disease duration, or severe secondary infections may experience persistent minor skin changes even after successful endocrine management. Regular veterinary monitoring through the recovery period ensures early detection and management of complications.

Frequently Asked Questions

References

1. Cerundolo, R., Lloyd, D. H., Persechino, A., Cocksedge, W., & Evans, H. (2007). Retrospective analysis of 157 cases of canine hyperadrenocorticism. Veterinary Record, 161(17), 523 to 525.
2. Reusch, C. E., & Feldman, E. C. (1998). Canine hyperadrenocorticism: Etiology, diagnosis, and management. Veterinary Clinics of North America: Small Animal Practice, 28(2), 205 to 232.
3. Helm, J. R., Milovancev, M., & Nydam, D. V. (2020). Cushingoid changes in a dog: Reversibility and correlation with serum cortisol concentrations. Journal of Small Animal Practice, 61(3), 154 to 158.
4. Ramsey, I. K., Evans, H., & Herrtage, M. E. (1999). Mitotane treatment of bilateral adrenocortical tumours in a dog. Journal of Small Animal Practice, 40(3), 120 to 124.
5. Lathan, P., & Mellor, D. J. (2009). The physiological stress response to Cushing's syndrome in dogs. Veterinary Dermatology, 20(4), 312 to 318.
6. Araujo, R. B., Gacek, F., Chiacchio, S. B., & Larsson, C. E. (2007). Dermatological manifestations of hyperadrenocorticism in 26 dogs. Veterinary Dermatology, 18(4), 246 to 252.
7. Barsanti, J. A., & Finco, D. R. (1984). Canine hyperadrenocorticism. In L. E. Bojrab (Ed.), Pathophysiology in small animal surgery (pp. 524 to 533). Lea & Febiger.
8. Kintzer, P. P., & Peterson, M. E. (1997). Mitotane treatment of primary hyperadrenocorticism in 11 dogs. Journal of the American Veterinary Medical Association, 210(3), 378 to 382.
9. Neiger, R. (2003). Canine hyperadrenocorticism. In R. W. Nelson & C. G. Couto (Eds.), Small animal internal medicine (3rd ed., pp. 1015 to 1032). Mosby.
10. Scott-Moncrieff, J. C., & Kintzer, P. P. (2015). Hyperadrenocorticism. In E. C. Feldman, R. W. Nelson, C. E. Reusch, & J. C. Scott-Moncrieff (Eds.), Canine and feline endocrinology (4th ed., pp. 352 to 406). Elsevier Saunders.

E. Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.

Research basis: All Vetified content references peer reviewed research published in journals including Veterinary Dermatology, JAVMA, and Journal of Small Animal Practice.